Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Presses Chinese API Firms Over Quality Concerns

Executive Summary

Tougher regulatory scrutiny by India amid its massive reliance on such raw materials from China is anticipated, but the current Indian inspection action is just 'normal regulatory duties,' a Shanghai-based regulatory officer said.

You may also be interested in...



China API Alert, Indian Firms Brace For More Pain

Prices of active pharmaceutical ingredients and intermediates from China have gone up significantly, piling pressure on Indian and Western companies that rely on it for supplies. Some firms are scrambling to draw up a plan B to secure supplies as the Asian giant weeds out polluting units and ups compliance.

China Zero Tariffs For Cancer Drugs Precede High-Stakes Trade Talks

China is opening up its domestic pharma market with an import duty exemption on 28 drugs including anticancers, effective May. The duty cuts came ahead of the latest trade talks between the US and China, though Chinese officials have underscored that countries like India could also stand to gain.

Innovation The Big Winner As China Joins ICH

Patients, international companies, and innovation-driven firms are set to gain the most from China’s dramatic move to join the ICH process, says one regulatory affairs veteran.

Topics

UsernamePublicRestriction

Register

PS122280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel